Vemurafenib in melanoma

Expert Review of Anticancer Therapy

Volumn 13, Issue 5, 2013, Pages 513-522

  Shaw, Heather M ^a   Nathan, Paul D ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

BRAF; melanoma; vemurafenib; Zelboraf

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; TEMOZOLOMIDE; VEMURAFENIB;

ALOPECIA; ARTHRALGIA; BRAF GENE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG TARGETING; DRUG WITHDRAWAL; DYSESTHESIA; FATIGUE; GENE; GENE MUTATION; HUMAN; KERATOACANTHOMA; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRURITUS; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; INDOLES; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84876858957     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.24     Document Type: Review

References (90)

1. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to BRAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010).
2. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009).
3. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 4(12), 748-759 (2003).
4. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat. Rev. 33(8), 665-680 (2007).
5. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
6. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
7. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
8. Wellbrock C, Ogilvie L, Hedley D et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64(7), 2338-2342 (2004).
9. Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30(20), 2522-2529 (2012).
10. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16(3), 368-377 (2009).
11. Becker TM, Philipsz S, Scurr LL et al. Oncogenic B-RAF(V600E) promotes anchorage-independent survival of human melanocytes. J. Invest. Dermatol. 130(8), 2144-2147 (2010).
12. Cartlidge RA, Thomas GR, Cagnol S et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 21(5), 534-544 (2008).
13. Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24(7), 2923-2931 (2004).
14. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3(7), e2734 (2008).
15. Satyamoorthy K, Li G, Gerrero MR et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63(4), 756-759 (2003).
16. Bottos A, Martini M, Di Nicolantonio F et al. Targeting oncogenic serine/ threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc. Natl Acad. Sci. USA 109(6), E353-E359 (2012).
17. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65(6), 2412-2421 (2005).
18. Arozarena I, Sanchez-Laorden B, Packer L et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMPspecific phosphodiesterase PDE5A. Cancer Cell 19(1), 45-57 (2011).
19. Gaggioli C, Robert G, Bertolotto C et al. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J. Invest. Dermatol. 127(2), 400-410 (2007).
20. Wan PT, Garnett MJ, Roe SM et al.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6), 855-867 (2004).
21. Laud K, Kannengiesser C, Avril MF et al.; French Herediatary Melanoma Study Group. BRAF as a melanoma susceptibility candidate gene? Cancer Res. 63(12), 3061-3065 (2003).
22. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
23. Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
24. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366(8), 707-714 (2012).
25. Rapp UR, Goldsborough MD, Mark GE et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl Acad. Sci. USA 80(14), 4218-4222 (1983).
26. Sithanandam G, Kolch W, Duh FM, Rapp UR. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 5(12), 1775-1780 (1990).
27. Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K, Rapp UR. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene 7(4), 795-799 (1992).
28. Emuss V, Garnett M, Mason C, Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 65(21), 9719-9726 (2005).
29. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11(11), 761-774 (2011).
30. Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol. Histopathol. 24(5), 643-650 (2009).
31. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353(20), 2135-2147 (2005).
32. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63(17), 5198-5202 (2003).
33. Hoeflich KP, Gray DC, Eby MT et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66(2), 999-1006 (2006).
34. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653(1), 25-40 (2003).
35. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4(2), 95-98 (2003).
36. Houben R, Becker JC, Kappel A et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3(1), 6 (2004).
37. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9(17), 6483-6488 (2003).
38. Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29(10), 1239-1246 (2011).
39. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8(3), 219-225 (2001).
40. Eisen T, Marais R, Affolter A et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: Phase I and open-label Phase II studies. Br. J. Cancer 105(3), 353-359 (2011).
41. Flaherty KT, Schiller J, Schuchter LM et al. A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14(15), 4836-4842 (2008).
42. Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27(17), 2823-2830 (2009).
43. Rabal O, Urbano-Cuadrado M, Oyarzabal J. Computational medicinal chemistry in fragment-based drug discovery: what, how and when. Future Med. Chem. 3(1), 95-134 (2011).
44. Surade S, Blundell TL. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 19(1), 42-50 (2012).
45. Barelier S, Krimm I. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. Curr. Opin. Chem. Biol. 15(4), 469-474 (2011).
46. Zhang C, Bollag G. Scaffold-based design of kinase inhibitors for cancer therapy. Curr. Opin. Genet. Dev. 20(1), 79-86 (2010).
47. Xie P, Streu C, Qin J et al. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry 48(23), 5187-5198 (2009).
48. Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105(8), 3041-3046 (2008).
49. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315), 596-599 (2010).
50. Joseph EW, Pratilas CA, Poulikakos PI et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107(33), 14903-14908 (2010).
51. Yang H, Higgins B, Kolinsky K et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70(13), 5518-5527 (2010).
52. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287), 427-430 (2010).
53. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287), 431-435 (2010).
54. Tap WD, Gong KW, Dering J et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12(8), 637-649 (2010).
55. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
56. Ribas A, Kim KB, Schuchter LM et al. BRIM-2: An open-label, multicenter Phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. ASCO Meeting Abstracts 29(15 Suppl.), 8509 (2011).
57. Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N. Biotechnol. 29(6), 682-688 (2012).
58. Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18(12), 3242-3249 (2012).
59. Greger JG, Eastman SD, Zhang V et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11(4), 909-920 (2012).
60. Davies MA, Liu P, McIntyre S et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8), 1687-1696 (2011).
61. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial. Lancet 379(9829), 1893-1901 (2012).
62. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N. Engl. J. Med. 365(25), 2439-2441 (2011).
63. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, Phase 2 trial. Lancet Oncol. 13(11), 1087-1095 (2012).
64. Shi H, Moriceau G, Kong X et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplificationmediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
65. Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377), 387-390 (2011).
66. Su F, Bradley WD, Wang Q et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72(4), 969-978 (2012).
67. Basile KJ, Abel EV, Aplin AE. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31(19), 2471-2479 (2012).
68. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 71(15), 5067-5074 (2011).
69. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6), 683-695 (2010).
70. Paraiso KH, Xiang Y, Rebecca VW et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71(7), 2750-2760 (2011).
71. Atefi M, von Euw E, Attar N et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 6(12), e28973 (2011).
72. Paraiso KH, Haarberg HE, Wood E et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin. Cancer Res. 18(9), 2502-2514 (2012).
73. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366(3), 207-215 (2012).
74. Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30(3), 316-321 (2012).
75. Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res. 70(21), 8475-8486 (2010).
76. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694-1703 (2012).
77. Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70(13), 5213-5219 (2010).
78. Huang RR, Jalil J, Economou JS et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin. Cancer Res. 17(12), 4101-4109 (2011).
79. Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2(4), 344-355 (2012).
80. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
81. Lin J, Goto Y, Murata H et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br. J. Cancer 104(3), 464-468 (2011).
82. Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30(20), 2522-2529 (2012).
83. Cancer Research UK: Cancer Statistics. http://info.cancerresearchuk.org/ cancerstats/types/skin/ incidence/#Malignant (Accessed 10 May 2012)
84. NCCN. NCCN Practice Guidelines in Oncology: melanoma. www.nccn.org/professionals/physician-gls/ pdf/melanoma.pdf (Accessed 10 May 2012)
85. Catalogue of Somatic Mutations in Cancer (COSMIC). www.sanger.ac.uk/ genetics/CGP/cosmic (Accessed 10 May 2012)
86. ClincalTrials.gov. Study of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc or Metastatic Melanoma and Activating Exon
87. BRAF Mutations Other than V600E. http://clinicaltrials.gov/ct2/show/ NCT015 86195?term=vemurafenib&rank=12 (Accessed 12 May 2012)
88. ClincalTrials.gov. A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases. http://clinicaltrials.gov/ct2/show/NCT013 78975?term=vemurafenib&rank=13 (Accessed 12 May 2012)
89. ClincalTrials.gov. Studies involving vemurafenib. http://clinicaltrials. gov/ct2/ results?term=vemurafenib (Accessed 13 May 2012)
90. ClincalTrials.gov. Ph I/II Ipilimumab Vemurafenib Combo. http://clinicaltrials.gov/ct2/show/NCT014 00451?term=vemurafenib&rank=7 (Accessed 13 May 2012)